Format

Send to

Choose Destination
J Neurol Sci. 2014 Nov 15;346(1-2):366-7. doi: 10.1016/j.jns.2014.09.008. Epub 2014 Sep 16.

Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.

Author information

1
Stroke Unit, Department of Neurology, Brugmann University Hospital, Brussels, Belgium. Electronic address: safouris@yahoo.com.
2
Hematology Department, Brugmann University Hospital, Brussels, Belgium.
3
First Department of Neurology, University of Athens, School of Medicine, "Eginition" University Hospital, Athens, Greece.
4
Second Department of Neurology, University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece; International Clinical Research Center, St. Anne's University Hospital in Brno, Czech Republic.
PMID:
25240443
DOI:
10.1016/j.jns.2014.09.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center